Skip to main content
SpringerLink
Log in

New indications for implantable defibrillator therapy

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Implantable cardioverter Defibrillator (ICD) therapy has been extensively evaluated in patients at high risk of sudden cardiac death. Most recently, the Sudden Cardiac Death in Heart Failure Trial found that patients with moderate symptoms of congestive heart failure, whether due to an ischemic or a nonischemic cause, have reduced mortality compared with patients treated only with conventional medical therapy for heart failure. The results of this trial confirm those of earlier trials finding a benefit of ICD therapy in patients with coronary artery disease and reduced left ventricular systolic function, and extend the indications for ICD therapy to those without coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable Defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576–1584.

    Article  Google Scholar 

  2. Connolly S, Gent M, Roberts R, et al.: Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter Defibrillator against amiodarone. Circulation 2000, 101:1297–1302.

    PubMed  CAS  Google Scholar 

  3. Kuck KH, Cappato R, Siebels J, Ruppel R: Randomized comparison of antiarrhythmic drug therapy with implantable Defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000 Aug 15, 102:748–754.

    PubMed  CAS  Google Scholar 

  4. Bigger JT Jr: Prophylactic use of implanted cardiac Defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997, 337:1569–1575.

    Article  PubMed  Google Scholar 

  5. Moss AJ, Hall WJ, Cannom DS, et al.: Improved survival with an implanted Defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933–1940.

    Article  PubMed  CAS  Google Scholar 

  6. Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators: Prophylactic implantation of a Defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883. This trial randomized 1,232 patients with CAD, low EF (< 30%) and prior MI to ICD therapy compared with standard background drug therapy. The study primary outcome demonstrated a significant survival advantage of ICD therapy (relative risk reduction of 31%) compared with good background drug therapy, (HR = 0.69,.95% CI: 51-.93; P = 0.007).

    Article  PubMed  Google Scholar 

  7. Kadish A, Dyer A, Daubert JP, et al., Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators: Prophylactic Defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 May 20, 350:2151–2158. The DEFINITE trial randomized 458 patients with nonischemic cardiomyopathy and LVEF of less than 35%, NYHA Class II or III heart failure symptoms to an ICD or no ICD. The relative risk reduction in total mortality for patients treated with an ICD was 35% (HR = 0.65; 95% CI, 0.40-1.06), which did not reach statistical significance (P = 0.08).

    Article  PubMed  CAS  Google Scholar 

  8. Bardy GH, Lee KL, Mark DB, et al., for the SCD-HeFT Investigators: Amiodarone or implantable cardioverter Defibrillator for congestive heart failure. N Engl J Med 2005, 352:225–237. The SCD-HeFT trial randomized 2521 patients equally to an ICD, placebo-controlled amiodarone, or good background heart failure therapy. The primary endpoint of the trial was total mortality. A statistically significant difference (relative risk reduction of 23%) was found between the ICD arm and the placebo arm of the trial but not between amiodarone therapy and placebo (ICD compared with placebo, HR = 0.77, 97.5% CI, 0.62-0.96; P = 0.007: amiodarone compared with placebo, HR = 1.06, 97.5% CI, 0.86-1.30).

    Article  PubMed  CAS  Google Scholar 

  9. Goldman S, Johnson G, Cohn JN, et al.: Mechanisms of death in heart failure: the vasodilator-heart failure trials. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:V124-V131.

    Google Scholar 

  10. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302.

    Article  Google Scholar 

  11. MERIT HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet 1999, 353:2001–2007.

    Article  Google Scholar 

  12. Julian DG, Camm AJ, Frangin G, et al., for the European Myocardial Infarct Amiodarone Trial Investigators: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997, 349:667–674.

    Article  PubMed  CAS  Google Scholar 

  13. Cairns JA, Connolly SJ, Roberts R, et al., for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997, 349:675–682.

    Article  PubMed  CAS  Google Scholar 

  14. Doval HC, Nul DR, Grancelli HO, et al., for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiac en Argentina (GESICA): Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493- 498.

    Article  PubMed  CAS  Google Scholar 

  15. Singh SN, Fletcher RD, Fisher SG, et al., for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995, 333:77–82.

    Article  PubMed  CAS  Google Scholar 

  16. Bardy GH, Troutman C, Poole JE, et al.: Clinical experience with a tiered therapy multiprogrammable antiarrhythmia device. Circulation 1992, 85:1689–1698.

    PubMed  CAS  Google Scholar 

  17. Wilkoff BL, Cook JR, Epstein AE, et al.: Dual-chamber pacing or ventricular backup pacing in patients with an implantable Defibrillator. The dual chamber and VVI implantable Defibrillator (DAVID) trial. JAMA 2002, 288:3115–3123.

    Article  PubMed  Google Scholar 

  18. Poole JE, Johnson GW, Callans DJ, et al.: Analysis of implantable Defibrillator shock electrograms in the Sudden Cardiac Death-Heart Failure Trial [abstract]. Heart Rhythm 2004, 1(Suppl 1):S178.

    Google Scholar 

  19. Packer DL, Bernstein R, Wood F, et al.: Impact of amiodarone versus implantable cardioverter Defibrillator therapy on the mode of death in congestive heart failure patients in the SCD-HeFT trial [abstract]. Heart Rhythm 2005, 2(Suppl 1):S38.

    Article  Google Scholar 

  20. Zareba W, Piotrowicz K, McNitt S, et al.: for the MADIT II Investigators: Implantable cardioverter-Defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 2005, 95:1487–1491.

    Article  PubMed  Google Scholar 

  21. Fishbein DP, Walsh MN, Poole JE, et al.: Baseline 6 minute walk distance in the Sudden Cardiac Death Heart Failure Trial [abstract]. Circulation 2004, 110(Suppl 3):III-676.

    Google Scholar 

  22. Bristow MR, Saxon LA, Boehmer J, et al., for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators: Cardiac-resynchronization therapy with or without an implantable Defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140–2150.

    Article  PubMed  CAS  Google Scholar 

  23. Cleland JG, Tavazzi L, Daubert JC, et al., for the CARE HF Investigators: The Cardiac resynchronization heart failure study (CARE-HF): a randomized study of the effects of optimal pharmacological therapy alone or combined with cardiac resynchronization in patients with advanced heart failure and cardiac dyssynchrony. N Engl J Med 2005, 352:1539–1549.

    Article  PubMed  CAS  Google Scholar 

  24. Poole JE, Anderson J, Johnson GW, et al.: Baseline ECG data and outcome in the sudden cardiac death-heart failure trial. Presented at the NASPE Heart Rhythm Society 19th annual scientfic sessions. San Diego, CA: May 19-22, 2004.

  25. Mark DB, Nelson CL, Anstrom KJ, et al., for the SCD-HeFT Investigators: Cost-effectiveness of ICD therapy in the sudden cardiac death in heart failure trial (SCD-HeFT). Circulation 2005, in press.

  26. Nudell BM: Congestive heart failure incidence and prevalence and ICD/CRT use. Bernstein Research Call. New York: Sanford C. Bernstein; 2004:1–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356422, 98195-6422, Seattle, WA, USA

    Jeanne E. Poole MD

Authors
  1. Jeanne E. Poole MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeanne E. Poole MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poole, J.E. New indications for implantable defibrillator therapy. Curr Cardiol Rep 8, 330–335 (2006). https://doi.org/10.1007/s11886-006-0071-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-006-0071-5

Keywords

Search

Navigation